Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Azacitidine
Disease-Free Survival
Dose-Response Relationship, Drug
Female
Humans
Leukemia, Myeloid, Acute
Male
Maximum Tolerated Dose
Middle Aged
Myelodysplastic Syndromes
Neoplasm Staging
Prognosis

authors with profiles

HAGOP M KANTARJIAN
ELIAS JOSEPH JABBOUR
NAVAL DAVER